Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Novartis

Status and phase: Completed; Phase 4

Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD)

Treatments: Drug: ranibizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00504959

CRFB002A2402

Details and patient eligibility

About

This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN

Enrollment: 234 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completion of 12-month treatment period of study CRFB002A2302 (EXCITE) or CRFB002A2303

Exclusion criteria

• Concurrent participation in another clinical trial, i.e. use of other investigational drugs

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

234 participants in 1 patient group

1

Experimental group

Description:

ranibizumab

Treatment:

Drug: ranibizumab